$ cat ./records/gates-foundation-backs-development-of-next-generation-bm86-based--2018.txt
Gates Foundation Backs Development of Next-Generation Bm86-Based Recombinant Tick Vaccine Optimised for African Rhipicephalus Strains
[RECORD.TXT] · cat --full
The original Bm86 gut-protein tick vaccine (commercialised as TickGARD in Australia and Gavac in Latin America in the 1990s) showed limited efficacy against African Rhipicephalus strains due to protein sequence divergence. The Gates Foundation funded researchers in South Africa and Kenya to characterise African Bm86 variants and engineer recombinant formulations optimised for the African tick populations that threaten smallholder cattle across the continent — a critical gap left unaddressed by commercially available products.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488784/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Pledged $4.1 million to Oxitec to develop a self-limiting strain of the malaria-transmitting Anopheles mosquito
Next →
Backed Malta Inc — molten-salt thermal storage to capture excess solar and wind electricity
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.